MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT

Neuroscience Letters

Volumn 593, Issue , 2015, Pages 1-6

  Bentea, Eduard ^a   Sconce, Michelle D ^b   Churchill, Madeline J ^b   Van Liefferinge, Joeri ^a   Sato, Hideyo ^d   Meshul, Charles K ^b,c   Massie, Ann ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NIIGATA UNIVERSITY   (Japan)

Author keywords

MPTP; Parkinson's disease; System xc ; XCT

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPORTER; DOPAMINE; PROTEIN; SYSTEM XC PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; XCT PROTEIN; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINO ACID TRANSPORTER; SLC7A11 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN HOMOGENATE; CELL COUNTING; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; FORELIMB; GENE LOSS; GENOTYPE; GRIP STRENGTH; GRIP STRENGTH TEST; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; CHEMICALLY INDUCED; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PARKINSONISM; PATHOPHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; CORPUS STRIATUM; DOPAMINE; FORELIMB; MALE; MICE, KNOCKOUT; NEURONS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84924760309     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.03.013     Document Type: Article

References (26)

1. Anglade P., Mouatt-Prigent A., Agid Y., Hirsch E. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 1996, 5(2):121-128.
2. Bagga P., Chugani A.N., Varadarajan K.S., Patel A.B. In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment. J. Neurochem. 2013, 127(3):365-377.
3. Bridges R., Lutgen V., Lobner D., Baker D.A. Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (system xc-) to normal and pathological glutamatergic signaling. Pharmacol. Rev. 2012, 64(3):780-802.
4. Burdo J., Dargusch R., Schubert D. Distribution of the cystine/glutamate antiporter system xc- in the brain, kidney, and duodenum. J. Histochem. Cytochem. 2006, 54(5):549-557.
5. Conrad M., Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x(c)(-): cystine supplier and beyond. Amino Acids 2012, 42(1):231-246.
6. De Bundel D., Schallier A., Loyens E., Fernando R., Miyashita H., Van Liefferinge J., Vermoesen K., Bannai S., Sato H., Michotte Y., Smolders I., Massie A. Loss of system x(c)- does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J. Neurosci. 2011, 31(15):5792-5803.
7. Dexter D.T., Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biol. Med. 2013, 62:132-144.
8. Duty S., Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011, 164(4):1357-1391.
9. Ferraro T.N., Golden G.T., DeMattei M., Hare T.A., Fariello R.G. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology 1986, 25(9):1071-1074.
10. Goldberg N.R., Haack A.K., Lim N.S., Janson O.K., Meshul C.K. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2011, 180:256-271.
11. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11(10):682-696.
12. Kobayashi S., Kuwata K., Sugimoto T., Igarashi K., Osaki M., Okada F., Fujii J., Bannai S., Sato H. Enhanced expression of cystine/glutamate transporter in the lung caused by the oxidative-stress-inducing agent paraquat. Free Radical Biol. Med. 2012, 53(12):2197-2203.
13. La Bella V., Valentino F., Piccoli T., Piccoli F. Expression and developmental regulation of the cystine/glutamate exchanger (xc-) in the rat. Neurochem. Res. 2007, 32(6):1081-1090.
14. Lewerenz J., Hewett S.J., Huang Y., Lambros M., Gout P.W., Kalivas P.W., Massie A., Smolders I., Methner A., Pergande M., Smith S.B., Ganapathy V., Maher P. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 2013, 18(5):522-555.
15. Lewerenz J., Maher P., Methner A. Regulation of xCT expression and system x(c)(-) function in neuronal cells. Amino Acids 2012, 42(1):171-179.
16. Massie A., Schallier A., Kim S.W., Fernando R., Kobayashi S., Beck H., De Bundel D., Vermoesen K., Bannai S., Smolders I., Conrad M., Plesnila N., Sato H., Michotte Y. Dopaminergic neurons of system x(c)(-) - deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. FASEB J. 2011, 25(4):1359-1369.
17. Massie A., Schallier A., Mertens B., Vermoesen K., Bannai S., Sato H., Smolders I., Michotte Y. Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats. Neuroreport 2008, 19(16):1589-1592.
18. Meredith G.E., Totterdell S., Beales M., Meshul C.K. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp. Neurol. 2009, 219(1):334-340.
19. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2004, Elsevier Academic Press, Amsterdam, Boston.
20. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 1986, 67(3):269-274.
21. Pow D.V. Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminoadipic acid, a selectively transported substrate. Glia 2001, 34(1):27-38.
22. Przedborski S., Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:189-198.
23. Robinson S., Freeman P., Moore C., Touchon J.C., Krentz L., Meshul C.K. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp. Neurol. 2003, 180(1):74-87.
24. Sato H., Shiiya A., Kimata M., Maebara K., Tamba M., Sakakura Y., Makino N., Sugiyama F., Yagami K., Moriguchi T., Takahashi S., Bannai S. Redox imbalance in cystine/glutamate transporter-deficient mice. J. Biol. Chem. 2005, 280(45):37423-37429.
25. Shibasaki T., Iuchi Y., Okada F., Kuwata K., Yamanobe T., Bannai S., Tomita Y., Sato H., Fujii J. Aggravation of ischemia-reperfusion-triggered acute renal failure in xCT-deficient mice. Arch. Biochem. Biophys. 2009, 490(1):63-69.
26. Zhang Y., Chen K., Sloan S.A., Bennett M.L., Scholze A.R., O'Keeffe S., Phatnani H.P., Guarnieri P., Caneda C., Ruderisch N., Deng S., Liddelow S.A., Zhang C., Daneman R., Maniatis T., Barres B.A., Wu J.Q. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014, 34(36):11929-11947.